Aileron Therapeutics, Inc.
ALRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | 0.02 | -0.15 | 0.04 |
| FCF Yield | -54.03% | -141.22% | -231.13% | -47.82% |
| EV / EBITDA | -0.44 | 0.21 | -0.20 | -1.76 |
| Quality | ||||
| ROIC | -115.36% | -16.01% | -147.93% | -59.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.35 | 1.26 | 0.91 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -12.54% | 20.34% | -3.99% | -16.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 1.11 | 0.19 | 0.13 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,650.00 | -3,714.79 | -3,650.00 |